Biostate AI secures $12M in Series A funding led by Accel to enhance RNA sequencing services for precision medicine.
May 20, 2025•2 months ago
Amount Raised
$12 Million
Investors
Accel
Description
Biostate AI has completed a $12M Series A funding round to advance RNA sequencing for molecular diagnostics. Led by Accel, the funding aims to revolutionize accessibility and integration of precision medicine. Co-founders Ashwin Gopinath and David Zhang focus on utilizing comprehensive RNA analyses. Their goal is to create predictive models that lead to personalized therapeutics.
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech